HLS Therapeutics (HLS) investor relations material

Business overview and strategy

• Focuses on neuro/psychiatric disorders and cardiovascular diseases with a profitable, growing product portfolio across North America.

• Operates with a model of acquiring US/Canadian rights to commercialize specialty pharmaceutical assets.

• Cardiovascular franchise includes Vascepa, NILEMDO, and NEXLIZET, while neuro/psychiatric includes Clozaril and companion diagnostics.

• Market cap of C$140M as of April 2026, with headquarters in Toronto and operations in Philadelphia, Montreal, and Barbados.

Financial performance and operational improvements

• Achieved a 25% reduction in operating expenses over two years.

• Adjusted EBITDA grew 83% (excluding royalties) in two years.

• Cash from operations increased by 114% from 2024 to 2025.

• Net debt reduced by 50% over three years.

Product portfolio and growth drivers

• Vascepa and NILEMDO are key cardiovascular products, with NEXLIZET pending approval.

• Clozaril remains a stable base, contributing $27M in 2025 and holding ~50% branded share in Canada.

• CSAN support network and MyCare therapeutic drug monitoring enhance patient compliance and generate additional revenue.

• Vascepa demonstrated 25% relative risk reduction in major adverse CV events and continues strong prescription growth (+45% CAGR 2022-2025).